News

Oncology nurses may experience a high level of bullying from their peers, but steps can be taken to improve the environment of the workplace.

Patients with high-risk mantle cell lymphoma are likely to have their disease relapse, making investigations into novel treatments, such as CAR T-cell therapy, important.

Nurses, patients, and caregivers can now have crucial information regarding medical devices sent directly to their smartphone.

Some patients with advanced ovarian cancer may be better candidates for primary debulking surgery, while others should start chemotherapy.

Light therapy can be used to prevent oral mucositis in patients with cancer, according to one expert.

Despite most wishing to die at home, nearly a third of patients with cancer die in the hospital. Goals-of-care discussions with nurses and other providers can help bring that number down.

Multiple Initiatives Contribute to ESPY Week Fundraising

An oncology nurse started a grassroots campaign that brought together community members and patients on the oncology unit.

A person’s HIV status should not be the sole reason they are excluded from a cancer clinical trial, according to recent research.

Symptom management and proper risk stratification are two crucial ways to improve the care of patients with myeloproliferative neoplasms, according to one expert.

By better understanding the subtypes of breast cancer, clinicians can create more personalized and effective treatment plans for patients with breast cancer.

After her sister passed away from hepatocellular carcinoma, Andrea Wilson started Blue Faery: The Adrienne Wilson Liver Cancer Association.

When it comes to molecular testing to advance the field of lung cancer, coordinated efforts between providers—and institutions nationwide—are key.

CLR 131, a targeted, molecular radiotherapy, showed a 33% overall response rate in patients with diffuse large B-cell lymphoma.

Now that the CD19-targeted CAR T-cell therapies axicabtagene ciloleucel (axi-cel; Yescarta) and tisagenlecleucel (Kymriah) have shown durable responses in the relapsed/refractory settings of non-Hodgkin lymphoma, researchers are hopeful that earlier exposure may heighten the curative potential of the modality, explained Mazyar Shadman, MD, MPH.

Now that patients have more drug options to treat myeloma, quality of life is becoming more important, said one expert.

An expert discusses the cardiac toxicity of ABP 980, a trastuzumab biosimilar, in the breast cancer space.

An expert gives an overview of how CDK4/6 inhibitors changed the treatment landscape for patients with metastatic breast cancer.

The Food and Drug Administration (FDA) approved selinexor (Xpovio) plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma, who had at least 4 prior therapies.

As the number of cancer diagnoses continues to increase across the United States it is crucial that primary care providers know when to refer patients to oncology teams.

Here are the top 5 Oncology Nursing News stories for June 2019.

Switch maintenance treatment with pembrolizumab (Keytruda) improved progression-free survival (PFS) in patients with metastatic urothelial cancer who have stable disease following frontline platinum-based chemotherapy, according to results of a randomized phase II study that were presented at the 2019 ASCO Annual Meeting.

The Food and Drug Administration approved bevacizumab-bvzr (Zirabev) – a biosimilar for bevacizumab (Avastin) for the treatment of metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic renal cell carcinoma; and persistent, recurrent or metastatic cervical cancer.

The Food and Drug Administration approved daratumumab (Darzalex) plus lenalidomide and dexamethasone (Rd) for the treatment of patients with newly diagnosed myeloma who are not eligible for autologous stem cell transplant (ASCT), according to Janssen, the manufacturer of the drug.

With a goal of championing the value of patient navigators, Susan G. Komen Greater New York City and NYU Langone have teamed up to provide patients with improved care in Brooklyn through a new patient navigation project.

The Food and Drug Administration lifted a partial clinical hold on the CANOVA trial, examining venetoclax with dexamethasone in relapsed/refractory myeloma.

While clinical trials drive FDA approvals, real-world data may be equally important as it lends insight to a broader group of patients.

The FDA has granted a priority review designation to a supplemental biologics license application for niraparib (Zejula) for the treatment of patients with advanced ovarian cancer.